The Department of Health and Social Care published the fifth England Rare Diseases Action Plan on 14 April 2026, setting out the next year's implementation of the UK Rare Diseases Framework. The plan is built around four priorities inherited from the framework: faster diagnosis, better awareness among healthcare professionals, better coordination of care and better access to specialist treatments and drugs.

Community pharmacy is not the headline setting for rare diseases. Specialist secondary and tertiary centres, homecare providers and highly specialised commissioning dominate the direct clinical pathway. But community pharmacy is increasingly part of the delivery picture — in dispensing, in medicines optimisation, in transitions of care, and in patient-facing advice where the specialist team is several hours or several months away.

This piece summarises the 2026 plan and draws out the practical implications for UK community pharmacy teams.

What the plan actually commits to

The action plan carries forward work streams from earlier plans rather than announcing a wholesale reset. Recurring themes in the 2026 document include:

• Continuing rollout of the Generalist Genomics Education Framework so GPs and other frontline professionals can recognise rare-disease presentations earlier.
• Expansion of the National Genomic Research Library and continued integration of genomic testing with the NHS Genomic Medicine Service.
• Work with NHS England on access pathways for highly specialised treatments, including the Innovative Medicines Fund and the Advanced Therapy Medicinal Product (ATMP) commissioning framework.
• Better use of the NHS App, electronic prescribing and digital records to coordinate care across the specialist centres and community services a rare-disease patient typically touches.
• Continued support for patient organisations and peer networks, which often fill information gaps that formal services leave open.

The framework structure — four priorities, annual action plans, quarterly reporting — has been consistent since 2021 and the 2026 plan sustains that architecture.

Why rare disease is a community pharmacy issue

There are approximately 7,000 recognised rare diseases; collectively they affect around 3.5 million people in the UK. Most rare-disease patients encounter community pharmacy far more often than their specialist centre. Three touchpoints matter.

Dispensing and supply. Rare-disease medicines increasingly involve a mix of hospital-only, homecare-only and community-dispensed items. Medicines for long-term maintenance — for example those used for cystic fibrosis, phenylketonuria, long-chain fatty acid oxidation disorders (covered in our triheptanoin piece), Fabry disease, hereditary angio-oedema — often generate ancillary community prescriptions for antihypertensives, analgesics, anti-infectives, enteral feed adjuncts or PRN reliever medication. A community pharmacy may be the continuity provider even when the rare-disease drug itself is delivered by homecare.

Medicines reconciliation. Rare-disease patients typically have complex polypharmacy across multiple prescribers. When a patient is discharged from a specialist admission or switches therapy, the community pharmacy is well placed to identify mismatches between the specialist summary, the GP record and what is actually dispensed.

Signposting and patient support. Patient organisations — Rare Disease UK, Genetic Alliance UK, Metabolic Support UK and condition-specific charities — are often the most effective information sources for families. Community pharmacy teams who know the landscape can signpost without over-promising.

Practical implications flowing from the 2026 plan

1. Better cross-setting prescribing information. The plan's digital-care stream should, over the next two to three years, make it easier for a community pharmacy to see what a specialist centre has started or changed. Pharmacy teams should be ready to use that information when it arrives and to flag where shared records remain incomplete.

2. More ATMPs in the pipeline. Advanced therapy medicinal products — gene therapies, cell therapies, tissue-engineered products — are delivered in specialised centres rather than community pharmacy. But patients receiving them still need continuity prescriptions, supportive care, adherence conversations and, increasingly, long-term monitoring organised in primary care. Awareness of the ATMP landscape helps community teams recognise these patients.

3. More newborn screening conditions. The UK newborn blood spot screening programme continues to expand, with additional conditions under consideration. Community pharmacy receives the first prescriptions — lifelong dietary adjuncts, enzyme replacements, emergency regimens — that follow newborn screening diagnoses. Understanding the screening panel and the medicines that attach to each condition helps the first dispensing go smoothly.

4. Patient organisation signposting. The action plan continues to fund work with patient organisations. Community pharmacy teams who can name the relevant patient organisation for a condition add real value — families often do not know these exist. NHS Rare Disease UK is a reasonable starting point for general enquiries.

5. Transition from paediatric to adult services. The transition from paediatric to adult care is repeatedly flagged as a weak point for rare disease. Young adults entering adult pharmacy services with complex long-term medication plans benefit from a community pharmacy team that notices and flags issues — dosing changes that were not made, repeat prescriptions that lapsed, new adult-service contacts that have not yet been added to records.

What community pharmacy is not expected to do

The 2026 plan does not position community pharmacy as a diagnostic hub for rare disease. Rare-disease diagnosis is a specialist activity, informed by genomics and by the generalist education streams the framework supports. A community pharmacy that spots a pattern — for example, a young adult with atypical severe bruising on repeat prescriptions that do not match — should signpost to the GP, not attempt to work up a condition from counter conversation.

The plan also does not expand community-pharmacy reimbursement for rare-disease activity. Dispensing rare-disease medicines remains within the existing Drug Tariff and specialist-commissioning architecture. Financial incentives that would pay for rare-disease-specific MURs or specialist counselling are not in this year's document.

A short decision framework for the pharmacy counter

Reading the plan itself

The document is comparatively short by policy-paper standards and readable in an afternoon. Community pharmacy teams who want to understand the broader direction of rare-disease policy — and be ready to contribute as digital, commissioning and workforce elements mature — will find it worth the time. The full text is available on gov.uk.

Further reading on PharmSee

• Triheptanoin for LC-FAOD: rare disease dispensing in community pharmacy
• DHSC and NHS Resolution framework: pharmacy indemnity
• Marketing authorisations 2025: new medicines in pharmacy dispensing

Find a UK community pharmacy on PharmSee.

Sources and caveats

Content drawn from the England Rare Diseases Action Plan 2026, the UK Rare Diseases Framework, the BNF and NHS England specialised commissioning resources. Rare-disease commissioning evolves rapidly; specific prescribing and supply pathways should be confirmed with the specialist centre or NHS England where relevant. This article is general pharmacy guidance, not personalised medical advice.